Epigenetic Basis of Cancer Drug Resistance

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582041

Authors

Moammir H Aziz

Aamir Ahmad

Affiliations

Soon will be listed here.

Citing Articles

SETDB1: an emerging target for anticancer drug development.

Trossini G, Hassanie H, Penteado A, El-Hajje M Future Med Chem. 2024; 17(2):153-155.

PMID: 39720918 PMC: 11749372. DOI: 10.1080/17568919.2024.2444869.

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.

SETDB1 as a cancer target: challenges and perspectives in drug design.

Hassanie H, Penteado A, de Almeida L, Calil R, da Silva Emery F, Costa-Lotufo L RSC Med Chem. 2024; 15(5):1424-1451.

PMID: 38799223 PMC: 11113007. DOI: 10.1039/d3md00366c.

Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.

Lafi Z, Alshaer W, Gharaibeh L, Alqudah D, AlQuaissi B, Bashaireh B PLoS One. 2023; 18(9):e0291981.

PMID: 37768997 PMC: 10538757. DOI: 10.1371/journal.pone.0291981.

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.

Nordin M, Azemi A, Nordin A, Nabgan W, Ng P, Yusoff K Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513835 PMC: 10386531. DOI: 10.3390/ph16070923.

References

White J, Pucci P, Crea F . The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors. Cancer Drug Resist. 2022; 2(2):326-334. PMC: 8992625. DOI: 10.20517/cdr.2019.16. View

Ediriweera M, Cho S . Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. Pharmacol Ther. 2019; 206:107437. DOI: 10.1016/j.pharmthera.2019.107437. View

Jia Z, Wang X, Zhang H . Overcome cancer drug resistance by targeting epigenetic modifications of centrosome. Cancer Drug Resist. 2022; 2(2):210-224. PMC: 8992632. DOI: 10.20517/cdr.2018.010. View

Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne C, Rimawi M . Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2019; 17(4):233-250. PMC: 8023395. DOI: 10.1038/s41571-019-0299-9. View

Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H . Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Oncogene. 2018; 37(31):4300-4312. PMC: 6072709. DOI: 10.1038/s41388-018-0276-2. View

Seno A, Mizutani A, Aizawa K, Onoue R, Masuda J, Ochi N . Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation. Cancer Drug Resist. 2022; 2(2):335-350. PMC: 8992628. DOI: 10.20517/cdr.2019.01. View

Biersack B . Alkylating anticancer agents and their relations to microRNAs. Cancer Drug Resist. 2022; 2(1):1-17. PMC: 9019174. DOI: 10.20517/cdr.2019.09. View

Schwarzenbach H, Gahan P . Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer Drug Resist. 2022; 2(2):271-296. PMC: 8992637. DOI: 10.20517/cdr.2019.010. View

Ponnusamy L, Mahalingaiah P, Chang Y, Singh K . Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug Resist. 2022; 2(2):297-312. PMC: 8992622. DOI: 10.20517/cdr.2018.11. View

10.

Ahmad A . Editorial: Cancer Epigenetics. Curr Cancer Drug Targets. 2018; 18(1):3-4. DOI: 10.2174/156800961801171208144307. View

11.

Lu Y, Liu Y, Oeck S, Glazer P . Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1. Mol Cancer Res. 2018; 16(10):1458-1469. PMC: 6170700. DOI: 10.1158/1541-7786.MCR-17-0637. View

12.

Malone E, Oliva M, Sabatini P, Stockley T, Siu L . Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1):8. PMC: 6961404. DOI: 10.1186/s13073-019-0703-1. View

13.

Ahmad A . Epigenetics in Personalized Management of Lung Cancer. Adv Exp Med Biol. 2015; 890:111-22. DOI: 10.1007/978-3-319-24932-2_6. View

14.

Meyer L, Hermiston M . The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. Cancer Drug Resist. 2022; 2(2):313-325. PMC: 8992636. DOI: 10.20517/cdr.2019.11. View

15.

Ahmad A, Li Y, Bao B, Kong D, Sarkar F . Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. Mol Nutr Food Res. 2013; 58(1):79-86. PMC: 3997058. DOI: 10.1002/mnfr.201300528. View

16.

Janczar S, Janczar K, Pastorczak A, Harb H, Paige A, Zalewska-Szewczyk B . The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia. Cancers (Basel). 2017; 9(1). PMC: 5295773. DOI: 10.3390/cancers9010002. View

17.

Galon J, Bruni D . Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity. 2020; 52(1):55-81. DOI: 10.1016/j.immuni.2019.12.018. View

18.

Ahmad A, Maitah M, Ginnebaugh K, Li Y, Bao B, Gadgeel S . Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol. 2013; 6(1):77. PMC: 3852827. DOI: 10.1186/1756-8722-6-77. View

19.

Ahmad A . Cancer Epigenetics: Clinical Perspectives. Curr Cancer Drug Targets. 2019; 19(7):513-514. DOI: 10.2174/156800961907190802112321. View

20.

Morales S, Monzo M, Navarro A . Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017; 8(5-6):203-212. DOI: 10.1515/bmc-2017-0024. View